Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

546 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.
Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Haddad N, Hurt KC, Llombart-Cussac A, Sledge GW. Neven P, et al. Clin Cancer Res. 2021 Nov 1;27(21):5801-5809. doi: 10.1158/1078-0432.CCR-20-4685. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376533
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Osborne CK, et al. Among authors: neven p. Clin Cancer Res. 2011 Mar 1;17(5):1147-59. doi: 10.1158/1078-0432.CCR-10-1869. Epub 2011 Jan 10. Clin Cancer Res. 2011. PMID: 21220480 Free PMC article. Clinical Trial.
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. Schuler M, et al. Among authors: neven p. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. doi: 10.1007/s10549-012-2126-1. Epub 2012 Jul 5. Breast Cancer Res Treat. 2012. PMID: 22763464 Free PMC article. Clinical Trial.
Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
Li W, O'Shaughnessy J, Hayes D, Campone M, Bondarenko I, Zbarskaya I, Brain E, Stenina M, Ivanova O, Graas MP, Neven P, Ricci D, Griffin T, Kheoh T, Yu M, Gormley M, Martin J, Schaffer M, Zelinsky K, De Porre P, Johnston SR. Li W, et al. Among authors: neven p. Clin Cancer Res. 2016 Dec 15;22(24):6002-6009. doi: 10.1158/1078-0432.CCR-15-2452. Epub 2016 Jun 7. Clin Cancer Res. 2016. PMID: 27267854 Clinical Trial.
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Musolino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, André F. Musolino A, et al. Among authors: neven p. Breast Cancer Res. 2017 Feb 10;19(1):18. doi: 10.1186/s13058-017-0807-8. Breast Cancer Res. 2017. PMID: 28183331 Free PMC article. Clinical Trial.
546 results